# Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

> **NCT03915184** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 105 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** zevor-cel

## Key facts

- **NCT ID:** NCT03915184
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915184, "Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03915184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*